Barchart.com
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Join Barchart Premier and get daily trading ideas and historical data downloads. FREE 30 Day Trial
Menu
Stocks | Futures | Watchlist | News | More
 
or
Watchlist | Portfolio | Dashboard
Site News
Contact
Market:
Faster, Cleaner, Better.
Menu

Immuneering Corp Cl A (IMRX)

Immuneering Corp Cl A (IMRX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
News & Headlines for [[ item.sessionDateDisplayLong ]]
Notes
Alerts
Watch
Help
Go To:
Immuneering to Present at the Piper Sandler 37th Annual Healthcare Conference GlobeNewswire - Tue Nov 25, 7:00AM CST

NEW YORK, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive and helping them thrive, today announced...

IMRX : 6.08 (-1.94%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B FinancialNewsMedia - Wed Nov 19, 8:45AM CST

EQNX::TICKER_START (NASDAQ:ONCY),(NASDAQ:ALXO),(NASDAQ:ERAS),(NASDAQ:IMRX),(NASDAQ:PRLD) EQNX::TICKER_END

ONCY : 0.9931 (-0.53%)
IMRX : 6.08 (-1.94%)
ALXO : 1.4700 (-3.29%)
ERAS : 3.60 (+6.51%)
PRLD : 1.7100 (+4.91%)
Targeted Cancer Therapies Gain Momentum as Precision Market Surges Past $106B GlobeNewswire - Wed Nov 19, 8:45AM CST

PALM BEACH, Fla., Nov. 19, 2025 (GLOBE NEWSWIRE) -- FN Media Group News Commentary - The precision oncology sector is experiencing unprecedented transformation as biomarker-driven therapies and...

ONCY : 0.9931 (-0.53%)
IMRX : 6.08 (-1.94%)
ALXO : 1.4700 (-3.29%)
ERAS : 3.60 (+6.51%)
PRLD : 1.7100 (+4.91%)
Immuneering Reports Third Quarter 2025 Financial Results and Provides Business and Clinical Updates GlobeNewswire - Wed Nov 12, 3:05PM CST

- Announced extraordinary 86% overall survival at 9 months in first-line pancreatic cancer patients treated with atebimetinib + mGnP - - Raised $225 million of financing, including $25 million private...

IMRX : 6.08 (-1.94%)
Immuneering to Report Third Quarter 2025 Financial Results and Provide New Clinical Case Studies, on Wednesday, November 12, 2025 GlobeNewswire - Tue Nov 4, 3:05PM CST

- New case studies on first-line pancreatic cancer patients treated with atebimetinib in combination with FOLFIRINOX to be shared by trial investigators – - Conference call scheduled for Wednesday,...

IMRX : 6.08 (-1.94%)
Analysts Offer Insights on Healthcare Companies: Immuneering (IMRX) and United Therapeutics (UTHR) Tipranks - Fri Oct 10, 6:24AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Immuneering (IMRX – Research Report) and United Therapeutics (UTHR – Research Report).Elevate Your Investing...

IMRX : 6.08 (-1.94%)
UTHR : 493.99 (+1.12%)
Mizuho Securities Remains a Buy on Immuneering (IMRX) Tipranks - Fri Oct 3, 6:22AM CDT

Mizuho Securities analyst Graig Suvannavejh reiterated a Buy rating on Immuneering today and set a price target of $10.00. The company’s shares closed yesterday at $6.36.Elevate Your Investing Strategy:...

IMRX : 6.08 (-1.94%)
Immuneering to Discuss Recently Announced Overall Survival Data from Phase 2a Clinical Trial of Atebimetinib + mGnP in First-Line Pancreatic Cancer Patients on Monday, September 29, 2025 GlobeNewswire - Fri Sep 26, 3:01PM CDT

NEW YORK, Sept. 26, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced that it will host a conference...

IMRX : 6.08 (-1.94%)
Immuneering Announces Pricing of $175 Million Underwritten Public Offering of Class A Common Stock and Concurrent $25 Million Private Placement of Class A Common Stock to Sanofi GlobeNewswire - Wed Sep 24, 11:08PM CDT

NEW YORK, Sept. 25, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced the pricing of its underwritten...

IMRX : 6.08 (-1.94%)
Immuneering Announces Proposed Underwritten Public Offering of Class A Common Stock and Pre-Funded Warrants and Proposed Concurrent Private Placement of Class A Common Stock and Class B Common Stock to Sanofi GlobeNewswire - Wed Sep 24, 3:05PM CDT

NEW YORK, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Immuneering Corporation (Nasdaq: IMRX), a clinical-stage oncology company focused on keeping cancer patients alive, today announced a proposed underwritten...

IMRX : 6.08 (-1.94%)

Barchart Exclusives

Inflation Data, AI Earnings and Other Can't Miss Items this Week Barchart - Sun Dec 14, 12:00PM CST
Markets enter a critical week still reeling from Friday's sharp selloff in technology and AI stocks following disappointing reactions to Oracle and Broadcom earnings that raised questions about AI infrastructure spending sustainability and return on massive capital investments. Here are 5 things to watch this week in the Market. Read more
Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
[[ data.userDate ]]
[[ data.eventTime | date: 'EEE, MMM dd, yyyy h:mm a' ]] [[ zone ]]
Reserve Your Spot